Daiichi Sankyo (OTCMKTS:DSNKY) Updates FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.870-0.870 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $14.7 billion-$14.7 billion, compared to the consensus revenue estimate of $13.4 billion.

Daiichi Sankyo Trading Down 11.5%

OTCMKTS:DSNKY traded down $2.09 during midday trading on Friday, hitting $16.14. 92,402 shares of the company traded hands, compared to its average volume of 217,207. The firm has a market capitalization of $30.07 billion, a P/E ratio of 17.17, a P/E/G ratio of 3.19 and a beta of -0.17. The firm’s fifty day moving average is $16.51 and its 200-day moving average is $17.73. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $27.50. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, sell-side analysts predict that Daiichi Sankyo will post 0.96 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on DSNKY shares. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday. Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.